Good morning. Here is my Monday morning deals summary of news I found from medtech and biotech last week. Headlines include surgicalOS technology, AI drug discovery, digital health, and more. Congratulations to all involved.
🔔 San Francisco-based startup Oath Surgical is partnering with tech giant Nvidia to enhance Oath’s artificial-intelligence-powered outpatient surgery centre operating system.
🔔 Qilu Pharmaceutical has struck a deal to tap into Insilico Medicine’s artificial intelligence drug development capabilities, offering up to $120 million to collaborate on small molecules for treating cardiometabolic diseases.
🔔 Medtronic has agreed to buy up to $90 million worth of shares in Anteris Technologies Global, developer of a transcatheter aortic valve replacement device for patients with severe aortic stenosis.
🔔 Evaro, an NHS-licensed digital healthcare platform based in Norwich, has closed a £18m Series A funding round. Founded in 2018, Evaro provides embeddable digital pharmacy infrastructure and prescribing tools.
🔔 French biotech company Sensorion announced today a €60m reserved offering including a €20 million strategic investment from Sanofi.
🔔 Dresden-based experts in sequence-precise gene repair, Seamless Therapeutics, have secured a heavyweight partner. The company has entered into a global research collaboration with the world’s largest pharmaceutical company by market cap, Eli Lilly
🔔 AstraZeneca is handing $1.2 billion in upfront cash to CSPC Pharmaceuticals for the ex-China rights to the biopharma’s once-monthly injectable weight management portfolio of eight programs
🔔 Moderna has out-licensed a rare disease drug candidate to Recordati, accepting $50 million upfront for an asset that could deliver registrational data this year.
🔔 Belgian Immunology biotech Agomab Therapeutics is seeking to raise up to $212.5 million in its Nasdaq debut, joining a series of biotechs chipping away at 2025’s iced-over IPO market.
🔔 With three Big Pharma collaborations already under its belt, Flagship Pioneering spinout Repertoire Immune Medicines has picked up another— signing a deal with Eli Lilly.
===============
Newton Colmore is a specialist search firm and we connect exceptional engineering and scientific talent with impactful companies, globally.